We are live on ! Find out more
PTIXW

Protagenic Therapeutics Warrant
PTIXW

Delisted

PTIXW was delisted on the 2nd of January, 2026.

Back to rankings

1 hedge funds and large institutions have $260K invested in Protagenic Therapeutics Warrant in 2021 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

3.45% more ownership

Funds ownership: 0% → 3.45% (+3.4%)

Holders
1
Holders Change
+1
Holders Change %
–
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
WAM
Warberg Asset Management
Illinois
+$168K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
WAM
1
Warberg Asset Management
Illinois
$260K +$168K +365,790 New

PTIXW Hedge Fund Activity: Q2 2021 in Review

1 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Protagenic Therapeutics Warrant (PTIXW) for Q2 2021, worth a combined $260K.

Buyers outnumbered sellers: 1 fund opened new PTIXW positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Warberg Asset Management, opening a new position worth an estimated $168K.

  • 1 institutional investor held Protagenic Therapeutics Warrant (PTIXW) as of Q2 2021, up from 0 in Q1 2021.
  • Funds reported $260K of Protagenic Therapeutics Warrant stock for Q2 2021.
  • 1 fund opened new Protagenic Therapeutics Warrant positions in Q2 2021 and 0 closed out, a net change of +1 holder.
  • The largest Protagenic Therapeutics Warrant buyer in Q2 2021 was Warberg Asset Management, an estimated $168K added.

Based on aggregated 13F filings for Q2 2021.